Rosiglitazone modulates the innate immune response to plasmodium falciparum infection and improves outcome in experimental cerebral malaria

Journal of Infectious Diseases

Volumn 199, Issue 10, 2009, Pages 1536-1545

  Serghides, Lena ^a,b   Patel, Samir N ^b,c   Ayi, Kodjo ^b,c   Lu, Ziyue ^b   Gowda, D Channe ^d   Liles, W Conrad ^a,b,c   Kain, Kevin C ^a,b,c  

^a Tropical Disease Unit   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD36 ANTIGEN; GLYCOSYLPHOSPHATIDYLINOSITOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; ROSIGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTIMALARIAL ACTIVITY; ARTICLE; BRAIN MALARIA; CONTROLLED STUDY; ENZYME INHIBITION; ERYTHROCYTE; EXPERIMENTAL INFECTION; EXPERIMENTAL MODEL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLAMMATION; INNATE IMMUNITY; MALARIA FALCIPARUM; MALE; MOUSE; NONHUMAN; PHAGOCYTOSIS; PLASMODIUM BERGHEI INFECTION; PLASMODIUM CHABAUDI INFECTION; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SURVIVAL RATE; TREATMENT OUTCOME; UPREGULATION;

ANIMALS; ANTIGENS, CD36; FLOW CYTOMETRY; HUMANS; IMMUNITY, INNATE; LEUKOCYTES, MONONUCLEAR; MACROPHAGES; MALARIA, CEREBRAL; MALARIA, FALCIPARUM; MICE; PHAGOCYTOSIS; PLASMODIUM FALCIPARUM; SIGNAL TRANSDUCTION; SURVIVORS; THIAZOLIDINEDIONES;

EID: 65549159340     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/598222     Document Type: Article

References (50)

1. World Health Organization. Severe falciparum malaria. Trans R Soc Trop Med Hyg 2000; 94(Suppl 1):S1-90.
2. John CC, Bangirana P, Opoka RO, et al. Cerebral malaria in children is associated with long-term cognitive impairment. Pediatrics 2008; 122: e1-8.
3. Hunt NH, Golenser J, Chan-Ling T, et al. Immunopathogenesis of cerebral malaria. Int J Parasitol 2006; 36:569-82.
4. White NJ. Not much progress in treatment of cerebral malaria. Lancet 1998; 352:594-5.
5. Dondorp A, Nosten F, Stepniewska K, Day N, White N. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. South East Asian Quinine Artesunate Malaria Trial Group. Lancet 2005; 366:717-25.
6. Stevenson MM, Riley EM. Innate immunity to malaria. Nat Rev Immunol 2004; 4:169-80.
7. Idro R, Jenkins NE, Newton CR. Pathogenesis, clinical features, and neurological outcome of cerebral malaria. Lancet Neurol 2005; 4:827-40.
8. Lamb TJ, Brown DE, Potocnik AJ, Langhorne J. Insights into the immunopathogenesis of malaria using mouse models. Expert Rev Mol Med 2006; 8:1-22.
9. Stevenson MM, Ghadirian E, Phillips NC, Rae D, Podoba JE. Role of mononuclear phagocytes in elimination of Plasmodium chabaudi AS infection. Parasite Immunol 1989; 11:529-54.
10. Su Z, Fortin A, Gros P, Stevenson MM. Opsonin-independent phagocytosis: an effector mechanism against acute blood-stage Plasmodium chabaudi AS infection. J Infect Dis 2002; 186:1321-9.
11. Patel SN, Lu Z, Ayi K, Serghides L, Gowda DC, Kain KC. Disruption of CD36 impairs cytokine response to Plasmodium falciparum GPI and confers susceptibility to severe and fatal malaria in vivo. J Immunol 2007; 178:3954-61.
12. Su Z, Stevenson MM. Central role of endogenous - interferon in protective immunity against blood-stage Plasmodium chabaudi AS infection. Infect Immun 2000; 68:4399-06.
13. Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 2007; 7:179-90.
14. Peiser L, Mukhopadhyay S, Gordon S. Scavenger receptors in innate immunity. Curr Opin Immunol 2002; 14:123-8.
15. Coban C, Ishii KJ, Kawai T, et al. Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin. J Exp Med 2005; 201:19-25.
16. Krishnegowda G, Hajjar AM, Zhu J, et al. Induction of proinflammatory responses in macrophages by the glycosylphosphatidylinositols of Plasmodium falciparum: cell signaling receptors, glycosylphosphatidylinositol (GPI) structural requirement, and regulation of GPI activity. J Biol Chem 2005; 280:8606-16.
17. Lu Z, Serghides L, Patel SN, et al. Disruption of JNK2 decreases the cytokine response to Plasmodium falciparum glycosylphosphatidylinositol in vitro and confers protection in a cerebral malaria model. J Immunol 2006; 177:6344-52.
18. Parroche P, Lauw FN, Goutagny N, et al. Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malariaDNAto Toll-like receptor 9. Proc Natl Acad SciUSA2007; 104: 1919-24.
19. Patel SN, Serghides L, Smith TG, et al. CD36 mediates the phagocytosis of Plasmodium falciparum-infected erythrocytes by rodent macrophages. J Infect Dis 2004; 189:204-13.
20. McGilvray ID, Serghides L, Kapus A, Rotstein OD, Kain KC. Nonopsonic monocyte/macrophage phagocytosis of Plasmodium falciparumparasitized erythrocytes: a role for CD36 in malarial clearance. Blood 2000; 96:3231-40.
21. Serghides L, Kain KC. Peroxisome proliferator activated receptor -retinoid X receptor agonists increase CD36-dependent phagocytosis of Plasmodium falciparum-parasitized erythrocytes and decrease malaria-induced TNF-alpha secretion by monocytes/macrophages. J Immunol 2001; 166:6742-8.
22. Hoebe K, Georgel P, Rutschmann S, et al. CD36 is a sensor of diacylglycerides. Nature 2005; 433:523-7.
23. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPAR- promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998; 93:241-52.
24. Malerod L, Sporstol M, Juvet LK, Mousavi A, Gjoen T, Berg T. Hepatic scavenger receptor class B, type I is stimulated by peroxisome proliferator-activated receptor - and hepatocyte nuclear factor 4alpha. Biochem Biophys Res Commun 2003; 305:557-5.
25. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W. The PPAR-leukotriene B4 pathway to inflammation control. Nature 1996; 384:39-43.
26. Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 2001; 169:453-9.
27. Poynter ME, Daynes RA. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-B signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 1998; 273:32833-41.
28. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor- is a negative regulator of macrophage activation. Nature 1998; 391:79-82.
29. Cheng-Lai A, Levine A. Rosiglitazone: an agent from the thiazolidinedione class for the treatment of type 2 diabetes. Heart Dis 2000; 2:326-33.
30. Grau GE, Fajardo LF, Piguet PF, Allet B, Lambert PH, Vassalli P. Tumor necrosis factor (cachectin) as an essential mediator in murine cerebral malaria. Science 1987; 237:1210-2.
31. Othoro C, Lal AA, Nahlen B, Koech D, Orago AS, Udhayakumar V. A low interleukin-10 tumor necrosis factor- ratio is associated with malaria anemia in children residing in a holoendemic malaria region in western Kenya. J Infect Dis 1999; 179:279-82.
32. Li C, Sanni LA, Omer F, Riley E, Langhorne J. Pathology of Plasmodium chabaudi chabaudi infection and mortality in interleukin-10-deficient mice are ameliorated by anti-tumor necrosis factor - and exacerbated by antitransforming growth factor - antibodies. Infect Immun 2003; 71:4850-6.
33. Omer FM, Riley EM. Transforming growth factor beta production is inversely correlated with severity of murine malaria infection. J Exp Med 1998; 188:39-48.
34. Day NP, Hien TT, Schollaardt T, et al. The prognostic and pathophysiologic role of pro- and antiinflammatory cytokines in severe malaria. J Infect Dis 1999; 180:1288-97.
35. Lyke KE, Burges R, Cissoko Y, et al. Serum levels of the proinflammatory cytokines interleukin-1 beta (IL-1-), IL-6, IL-8, IL-10, tumor necrosis factor -, and IL-12(p70) in Malian children with severe Plasmodium falciparum malaria and matched uncomplicated malaria or healthy controls. Infect Immun 2004; 72:5630-7.
36. Taylor-Robinson AW, Phillips RS. B cells are required for the switch from Th1- to Th2-regulated immune responses to Plasmodium chabaudi chabaudi infection. Infect Immun 1994; 62:2490-8.
37. Langhorne J, Cross C, Seixas E, Li C, von der Weid T. A role for B cells in the development of T cell helper function in a malaria infection in mice. Proc Natl Acad Sci U S A 1998; 95:1730-4.
38. Taylor PR, Seixas E, Walport MJ, Langhorne J, Botto M. Complement contributes to protective immunity against reinfection by Plasmodium chabaudi chabaudi parasites. Infect Immun 2001; 69:3853-9.
39. Newton CR, Krishna S. Severe falciparum malaria in children: current understanding of pathophysiology and supportive treatment. Pharmacol Ther 1998; 79:1-53.
40. Franke-Fayard B, Janse CJ, Cunha-Rodrigues M, et al. Murine malaria parasite sequestration: CD36 is the major receptor, but cerebral pathology is unlinked to sequestration. Proc Natl Acad Sci U S A 2005; 102: 11468-73.
41. Cortes A, Mellombo M, Mgone CS, Beck HP, Reeder JC, Cooke BM. Adhesion of Plasmodium falciparum-infected red blood cells to CD36 under flow is enhanced by the cerebral malaria-protective trait Southeast Asian ovalocytosis. Mol Biochem Parasitol 2005; 142:252-7.
42. Newbold C, Craig A, Kyes S, Rowe A, Fernandez-Reyes D, Fagan T. Cytoadherence, pathogenesis and the infected red cell surface in Plasmodium falciparum. Int J Parasitol 1999; 29:927-37.
43. Aitman TJ, Cooper LD, Norsworthy PJ, et al. Malaria susceptibility and CD36 mutation. Nature 2000; 405:1015-6.
44. Wassmer SC, Cianciolo GL, Combes V, Grau GE. Platelets reorient Plasmodium falciparum-infected erythrocyte cytoadhesion to activated endothelial cells. J Infect Dis 2004; 189:180-9.
45. Grau GE, Mackenzie CD, Carr RA, et al. Platelet accumulation in brain microvessels in fatal pediatric cerebral malaria. J Infect Dis 2003; 187:461-6.
46. Cholera R, Brittain NJ, Gillrie MR, et al. Impaired cytoadherence of Plasmodium falciparum-infected erythrocytes containing sickle hemoglobin. Proc Natl Acad Sci U S A 2008; 105:991-6.
47. Serghides L, Kain KC. Peroxisome proliferator-activated receptor - and retinoid X receptor agonists have minimal effects on the interaction of endothelial cells with Plasmodium falciparum-infected erythrocytes. Infect Immun 2005; 73:1209-13.
48. Weisman JL, Liou AP, Shelat AA, Cohen FE, Guy RK, DeRisi JL. Searching for new antimalarial therapeutics amongst known drugs. Chem Biol Drug Des 2006; 67:409-16.
49. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol 2004; 172:2731-8.
50. Perel P, Roberts I, Sena E, et al. Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ 2007; 334:197.